Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Novel Personalized Cellular Therapy approach for Immune Diseases

Reference number
Coordinator TLA TARGETED IMMUNO THERAPIES AB - TLA Targeted Immunotherapies AB
Funding from Vinnova SEK 500 000
Project duration July 2017 - December 2017
Status Completed

Purpose and goal

The aim of the project was to develop a business plan that w ill guide clinical validation and commercialization of the TLA medical device for the treatment of inflammatory bow eldisease (IBD).

Expected results and effects

The business plan has been developed and the market potential has been confirmed. The company is ready to initiate the clinical study. Market analysis has shown that the conditions for validation and commercialization of our product are good.

Planned approach and implementation

The project has been implemented using the Strategic Business Planning Methodology which includes the follow ing activities: Task 1 Strategic Business Review Task 2 Business Model Visioning Task 3 Business Plan Development and Formulation

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 14 June 2019

Reference number 2017-03375

Page statistics